Are Investors Undervaluing Sanofi (SNY) Right Now?
Press Release: Availability of the Q3 2024 Aide Mémoire
Amgen Stock Slides 5% as Analysts Weigh in on Drug Study Results
Amgen's Rocatinlimab Has Commercial Potential Despite Competitive Landscape, Says Goldman Sachs
Amgen's Rocatinlimab Data Beats Placebo In Atopic Dermatitis Trial, But Analyst Says Data Raises Concerns Amid Competitive Market
Sanofi:la Presidencia Polaca De La UE Allana El Camino Para Una Industria Farmacéutica Competitiva
Private Equity Firms Circle Sanofi's Consumer Health Business Amid Potential Spinoff
Sanofi's Market Advantage and Growth Trajectory: A Strong Buy Recommendation
Analysts Offer Insights on Healthcare Companies: Thermo Fisher (TMO), Cardinal Health (CAH) and Sanofi (OtherSNYNF)
Media Update: EADV: New Data Reinforce Sanofi's Innovative Approach and Leadership Across Immune-mediated Skin Diseases
Sanofi's Tolebrutinib Delays MS Disability Progression
Market Chatter: Sanofi Consumer Health Division Attracts Bids From 2 Private Equity Firms
Sanofi Gets Binding Bids for Consumer Unit: Bloomberg News
Sector Update: Health Care Stocks Decline Tuesday Afternoon
Sector Update: Health Care
Express News | 'Sanofi Gets Binding Bids From CD&R, PAI for Consumer Arm' - Bloomberg
Competition heats up in Sanofi's (SNY.US) consumer health department, with lenders preparing over 10 billion euros to support the acquisition battle.
Some core banks signed financing commitments for priority debt of 7.5 billion to 7.8 billion euros over the weekend to support the bid for this acquisition. They will also provide approximately 1.2 billion euros in revolving crediting facilities.
Lenders Commit Over $11 Billion for Buyout of Sanofi Consumer Health Unit, Bloomberg Reports
Lenders Line Up Over €10 Billion for Sanofi Health Unit Buyout
Sanofi's Promising Portfolio Drives Buy Rating Amid MS, Cancer Breakthroughs, and Vaccine Expansion